Acorai

COMPANY INFORMATION:

Acorai is developing a noninvasive intracardiac pressure device to improve heart failure workflows for more than 64 million patients worldwide. The FDA designated Acorai’s system a breakthrough device in 2023 and built upon the patented SAVE Sensor System, a proprietary, noninvasive hardware platform with machine learning.

Acorai is backed by Solaris Health Ventures, KHP Ventures, GA Investors, and Life Science Invest. It has a seasoned medical device team and corporate advisory board with experience from GE Healthcare, Abbott & United Healthcare, and it has established clinical partnerships with world-leading hospitals.  

PRODUCTS:

Acorai Non-invasive intracardiac pressure system. (For investigational use only)